Supeda Thongyen

Survival Rate and Risk Factors of Mortality Among HIV/Tuberculosis-Coinfected Patients With and Without Antiretroviral Therapy

Weerawat Manosuthi, Suthat Chottanapand, Supeda Thongyen et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2006 · 259 citations

Public Health, Infectious Diseases, Clinical Epidemiology +15

A Randomized Trial Comparing Plasma Drug Concentrations and Efficacies between 2 Nonnucleoside Reverse‐Transcriptase Inhibitor–Based Regimens in HIV‐Infected Patients Receiving Rifampicin: The N₂R Study

Weerawat Manosuthi, Somnuek Sungkanuparph, Preecha Tantanathip et al. · Clinical Infectious Diseases · 2009 · 114 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Time to Initiate Antiretroviral Therapy Between 4 Weeks and 12 Weeks of Tuberculosis Treatment in HIV-Infected Patients

Weerawat Manosuthi, Wiroj Mankatitham, Aroon Lueangniyomkul et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2012 · 52 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Impact of Pharmacogenetic Markers of<i>CYP2B6</i>, Clinical Factors, and Drug-Drug Interaction on Efavirenz Concentrations in HIV/Tuberculosis-Coinfected Patients

Weerawat Manosuthi, Chonlaphat Sukasem, Aroon Lueangniyomkul et al. · Antimicrobial Agents and Chemotherapy · 2012 · 40 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Incidence and risk factors of rash associated with efavirenz in HIV‐infected patients with preceding nevirapine‐associated rash

Weerawat Manosuthi, Supeda Thongyen, Noppanath Chumpathat et al. · HIV Medicine · 2006 · 35 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16